Pipeline



Pipeline Overview
We have assembled a robust portfolio of allogeneic iPSC-derived cell therapies in autoimmune disease and cancer. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses.
Product
iPSC PLATFORM
Allo-Evasion™
Targets
Indications
Clinical Trial
Research
Ind-enabling
Clinical
P1
P2
P3
Autoimmune Diseases
Solid Tumors
Malignancies
Undisclosed
1Agreement in place for an investigator-initiated trial (IIT) by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg. The CARAMEL trial is expected to commence in mid-2025 following CTA approval.